7394 Federal Register / Vol. 86, No. 17 / Thursday, January 28, 2021 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Actual Experiment 1—Mobile Robot ............................. 37 1 70/60 

Actual Experiment 2—Collaborative Robot .................. 37 1 70/60 

NASA Task Load Index ................................................ 37 63 1/60 

Perceived Safety Questionnaire ................................... 37 63 1/60 

Robot Trust Questionnaire ............................................ 37 63 1/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–01692 Filed 1–27–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–21–20QS] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Proposed Data 

Collection Multi-Site Clinical 

Assessment of Myalgic 

Encephalomyelitis/Chronic Fatigue 

Syndrome (MCAM)’’ to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a 60-day notice titled 

‘‘Proposed Data Collection Submitted 

for Public Comment and 

Recommendations’’ on August 3, 2020 

to obtain comments from the public and 

affected agencies. CDC received three 

comments related to the previous 

notice. This notice serves to allow an 

additional 30 days for public and 

affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Multi-Site Clinical Assessment of 

Myalgic Encephalomyelitis/Chronic 

Fatigue Syndrome (MCAM)—Existing 

collection in use without an OMB 

Control Number—National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

This Multi-site Clinical Assessment of 

Myalgic Encephalomyelitis/Chronic 

Fatigue Syndrome (MCAM) study uses a 

standardized approach for data 

collection to examine the heterogeneity 

of patients with Myalgic 

Encephalomyelitis/Chronic Fatigue 

Syndrome (ME/CFS) using a clinical 

epidemiologic longitudinal study with a 

retrospective and prospective rolling 

cohort design. The study also aims to 

address the issue of ME/CFS case 

definition and improve measures of 

illness domains by using evidencebased data from multiple clinical 

practices in the United States. Healthy 

adults and those with illnesses that 

share some features with ME/CFS were 

enrolled in comparison groups. 

Children and adolescents with ME/CFS 

and healthy participants were also 

enrolled. 

The MCAM study has been conducted 

in multiple stages following multiple 

study protocols. The time burden 

estimates are based on the 2012–2019 

data collection, which is the most recent 

stage of data collection completed. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of 

respondents Form name Number of participants 

Number of 

responses per 

participant 

Average 

burden per 

response 

(in hrs.) 

Adult ........................................ CDC Symptom Inventory (CDC–SI)/Form A .......................... 45 1 12/60 

Adult ........................................ CDC Symptom Inventory (CDC–SI)/Form B .......................... 20 1 10/60 

Adult ........................................ CDC Symptom Inventory (CDC–SI) ....................................... 20 1 8/60 

Adult ........................................ Short Form CDC–SI/Checklist ............................................... 85 1 10/60 

Adult ........................................ Medical Outcomes Study Short Form 36 ............................... 85 1 7/60 

Federal Register / Vol. 86, No. 17 / Thursday, January 28, 2021 / Notices 7395 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of 

respondents Form name Number of participants 

Number of 

responses per 

participant 

Average 

burden per 

response 

(in hrs.) 

Adult ........................................ Multidimensional Fatigue Inventory (MFI–20) ........................ 85 1 5/60 

Adult ........................................ DePaul Symptom Questionnaire (DSQ) ................................ 45 1 24/60 

Adult ........................................ DSQ, 26 selected questions .................................................. 65 1 12/60 

Adult ........................................ DSQ, 18 selected questions .................................................. 85 1 6/60 

Adult ........................................ PROMIS Short Form (PROMIS SF—Fatigue, SD, SRI, PB, 

PI) & Sleep Data Collection Form.

85 1 5/60 

Adult ........................................ PROMIS SF—Fatigue, SD, SRI, PB, PI ................................ 85 1 4/60 

Adult ........................................ Brief Pain Inventory (BPI) ...................................................... 85 1 13/60 

Adult ........................................ Patient Health Questionnaire (PHQ–8), Generalized Anxiety 

Disorder (GAD–7), CDC Health-Related Quality of Life 

(HRQoL–4).

85 1 10/60 

Adult ........................................ CDC HRQoL–4 ....................................................................... 85 1 3/60 

Adult ........................................ CDC HRQoL–4 with activity limitation questions ................... 85 1 4/60 

Adult ........................................ Self-Rating Depression Scale (SDS) ..................................... 45 1 7/60 

Adult ........................................ Illness Impact Questionnaire .................................................. 85 1 3/60 

Adult ........................................ Saliva Data Collection Sheet ................................................. 85 1 5/60 

Adult ........................................ Orthostatic Grading Scale (OGS) .......................................... 85 1 3/60

Adult ........................................ COMPosite Autonomic Symptom Score 31 (COMPASS–31) 85 1 5/60 

Adult ........................................ CDC Symptom Inventory (CDC–SI)/Form A .......................... 24 1 42/60 

Adult ........................................ CDC Symptom Inventory (CDC–SI)/Form B .......................... 30 1 20/60 

Adult ........................................ CDC Symptom Inventory (CDC–SI) ....................................... 15 1 10/60 

Adult ........................................ Short Form CDC–SI/Checklist ............................................... 69 1 20/60 

Adult ........................................ Medical Outcomes Study Short Form 36 ............................... 69 1 17/60 

Adult ........................................ Multidimensional Fatigue Inventory (MFI–20) ........................ 69 1 10/60 

Adult ........................................ DePaul Symptom Questionnaire (DSQ) ................................ 24 1 36/60 

Adult ........................................ DSQ, 26 selected questions .................................................. 45 1 18/60 

Adult ........................................ DSQ, 18 selected questions .................................................. 69 1 20/60 

Adult ........................................ PROMIS Short Form (PROMIS SF—Fatigue, SD, SRI, PB, 

PI) & Sleep Data Collection Form.

24 1 6/60 

Adult ........................................ PROMIS SF—Fatigue, SD, SRI, PB, PI ................................ 69 1 5/60 

Adult ........................................ Brief Pain Inventory (BPI) ...................................................... 24 1 13/60 

Adult ........................................ Patient Health Questionnaire (PHQ–8), Generalized Anxiety 

Disorder (GAD–7), CDC Health-Related Quality of Life 

(HRQoL–4).

24 1 10/60 

Adult ........................................ CDC HRQoL–4 ....................................................................... 69 1 4/60 

Adult ........................................ CDC HRQoL–4 with activity limitation questions ................... 69 1 7/60 

Adult ........................................ Self-Rating Depression Scale (SDS) ..................................... 24 1 7/60 

Adult ........................................ Illness Impact Questionnaire .................................................. 69 1 3/60 

Adult ........................................ Saliva Data Collection Sheet ................................................. 69 1 5/60 

Adult ........................................ Orthostatic Grading Scale (OGS) .......................................... 69 1 5/60

Adult ........................................ COMPosite Autonomic Symptom Score 31 (COMPASS–31) 69 1 7/60 

Pediatric .................................. CDC Symptom Inventory: For Baseline Subjects Pediatrics 36 1 8/60 

Pediatric .................................. CDC Symptom Inventory: For the Follow-Up Subjects Pediatrics.29 1 6/60 

Pediatric .................................. SF–36 Health Survey ............................................................. 64 1 5/60 

Pediatric .................................. Multidimensional Fatigue Inventory (MFI–20) ........................ 64 1 2/60 

Pediatric .................................. Selected Questions from DePaul Pediatric Health Questionnaire (DPHQ), 19 Questions.64 1 5/60 

Pediatric .................................. PROMIS Pediatric Instruments (Fatigue & Pain) ................... 64 1 2/60 

Pediatric .................................. Pediatric Pain Questionnaire (PPQ) ...................................... 64 1 7/60 

Pediatric .................................. Visual Analogue Scale ........................................................... 64 1 6/60 

Pediatric .................................. Hospital Anxiety and Depression Scale ................................. 64 1 5/60 

Pediatric .................................. Pediatric Daytime Sleepiness Scale ...................................... 64 1 2/60 

Pediatric .................................. Social Participation Form Pediatric ........................................ 64 1 7/60

Pediatric .................................. Sociability Form ...................................................................... 64 1 3/60 

Pediatric .................................. Saliva Collection Form ........................................................... 64 1 5/60 

Pediatric .................................. CDC Symptom Inventory: For Baseline Subjects Pediatrics 3 1 20/60 

Pediatric .................................. CDC Symptom Inventory: For the Follow-Up Subjects Pediatrics.3 1 9/60 

Pediatric .................................. SF–36 Health Survey ............................................................. 3 1 9/60 

Pediatric .................................. Multidimensional Fatigue Inventory (MFI–20) ........................ 3 1 7/60 

Pediatric .................................. Selected Questions from DePaul Pediatric Health Questionnaire (DPHQ), 19 Questions.3 1 10/60 

Pediatric .................................. PROMIS Pediatric Instruments (Fatigue & Pain) ................... 3 1 3/60 

Pediatric .................................. Pediatric Pain Questionnaire (PPQ) ...................................... 3 1 15/60 

Pediatric .................................. Visual Analogue Scale ........................................................... 3 1 8/60 

Pediatric .................................. Hospital Anxiety and Depression Scale ................................. 3 1 7/60 

Pediatric .................................. Pediatric Daytime Sleepiness Scale ...................................... 3 1 3/60 

Pediatric .................................. Social Participation Form Pediatric ........................................ 3 1 10/60

7396 Federal Register / Vol. 86, No. 17 / Thursday, January 28, 2021 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of 

respondents Form name Number of participants 

Number of 

responses per 

participant 

Average 

burden per 

response 

(in hrs.) 

Pediatric .................................. Sociability Form ...................................................................... 3 1 5/60 

Pediatric .................................. Saliva Collection Form ........................................................... 3 1 5/60 

Adult ........................................ CogState Practice Section ..................................................... 109 1 17/60 

Adult ........................................ CogState Baseline Section .................................................... 109 1 27/60 

Adult ........................................ WAIS IV DS F+B, TOPF ........................................................ 109 1 10/60 

Adult ........................................ Exercise (Bike) Testing .......................................................... 64 1 30/60 

Adult ........................................ CogState Time 1 Section ....................................................... 109 1 22/60 

Adult ........................................ CogState Time 2 Section ....................................................... 109 1 12/60 

Adult ........................................ CogState Time 3 Section ....................................................... 109 1 12/60 

Adult ........................................ CogState Time 4 Section ....................................................... 109 1 12/60 

Adult ........................................ Visual Analogue Scale for CFS Symptoms ........................... 60 1 8/60 

Adult ........................................ EQ–5D–Y Health Questionnaire ............................................ 60 1 6/60 

Adult ........................................ PROMIS SF v1—Physical Function ....................................... 60 1 5/60 

Adult ........................................ Physical Fitness and Exercise Activity Levels of Scale ......... 60 1 2/60 

Adult ........................................ International Physical Activity Questionnaire (Self-Administered Long Form).60 1 5/60 

Adult ........................................ Physical Activity Readiness Questionnaire ............................ 60 1 5/60 

Adult ........................................ Visual Analogue Scale for CFS Symptoms ........................... 49 1 8/60 

Adult ........................................ EQ–5D–Y Health Questionnaire ............................................ 49 1 6/60 

Adult ........................................ PROMIS SF v1—Physical Function ....................................... 49 1 5/60 

Adult ........................................ Physical Fitness and Exercise Activity Levels of Scale ......... 49 1 2/60 

Adult ........................................ International Physical Activity Questionnaire (Self-Administered Long Form).49 1 5/60 

Adult ........................................ Physical Activity Readiness Questionnaire ............................ 49 1 5/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–01914 Filed 1–27–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–21–1129] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled Improving Fetal 

Alcohol Spectrum Disorders Prevention 

and Practice through National 

Partnerships to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on October 

13, 2020 to obtain comments from the 

public and affected agencies. CDC did 

not receive comments related to the 

previous notice. This notice serves to 

allow an additional 30 days for public 

and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Improving Fetal Alcohol Spectrum 

Disorders Prevention and Practice 

through National Partnerships (OMB 

Control No. 0920–1129, Exp. 8/31/ 

2019)—Reinstatement with Change— 

National Centrer for Birth Defects and 

Developmental Disabilities (NCBDDD), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

The National Center on Birth Defects 

and Developmental Disabilities 

(NCBDDD) seeks to collect training 

evaluation data from healthcare 

practitioners and staff in health systems 

where FASD-related practice and 

systems changes are implemented, and 

from grantees of national partner 

organizations related to prevention, 

identification, and treatment of fetal 

alcohol spectrum disorders (FASDs). 

Prenatal exposure to alcohol is a 

leading preventable cause of birth 

defects and developmental disabilities.